-

12:41:06 AM

SLRX Stock News

SLRX - Salarius Pharmaceuticals Inc

01/13/22 7:00 AM

Nasdaq : SLRX

acquisition

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Conference call and live audio webcast scheduled for today at 8:30 a.m. EST Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug

RHEA-AI

neutral

01/06/22 12:45 PM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"

Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company will present at H.C. Wainwright BioConnect

RHEA-AI

neutral

12/29/21 8:03 AM

Nasdaq : SLRX

clinical trial

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

RHEA-AI

neutral

12/15/21 8:31 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

11/29/21 8:01 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, announced today that its chief executive

RHEA-AI

neutral

11/04/21 4:05 PM

Nasdaq : SLRX

earnings

Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat Added Five New Clinical Sites to Sarcoma Trial; 13 Active Sites Now Supporting Enrollment Initial Ewing Sarcoma Combination Therapy Safety Lead-in Cohort Fully

RHEA-AI

neutral

10/26/21 8:01 AM

Nasdaq : SLRX

conferencesearnings

Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,

RHEA-AI

neutral

10/07/21 9:05 AM

Nasdaq : SLRX

Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital announced today research

RHEA-AI

neutral

10/05/21 8:01 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief

RHEA-AI

neutral

09/30/21 4:35 PM

Nasdaq : SLRX

Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital disclosed today that an

RHEA-AI

neutral

1 2 3 4 5 6 Next

SLRX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitesalariuspharma.com
CeoDavid Arthur
Security nameSalarius Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Tags
- Health Technology
- Pharmaceuticals: Other
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2450 Holcombe Blvd Ste J-608
StateTexas
CityHouston
Zip77021-2041
CountryUS
Phone13467720346

SLRX Description:

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).